Funding

In August 2023, the 2023-2028 strategy for the “New Methods” framework was published. The strategy defines the most important objectives for further improvement of the framework over the next five years, including the development of appropriate processes and prioritization criteria for medical devices and procedures.

In August 2023, the Danish Health Technology Council (Behandlingsråd) decided to conduct evaluations based on completed health technology assessments (HTA) from other countries, adopting their results to the Danish context. This evaluation method will be introduced in addition to the currently used. The Council has already selected the first four HTAs for evaluation.

On June 13, 2023, the Swedish Medical Technologies Product (MTP) Council recommended that all regions delay the introduction of robotic systems for knee, hip, and spine surgery until they have been evaluated as part of the Orderly introduction framework. For now, MTP Council recommends robotic systems in these indications only to be used in the context of research.

In May 2023, the latest set of guidance (List 3) of the Evidence-based Interventions (EBI) Programme was published. The program is run by the Academy of Medical Royal Colleges (AoMRC), supported by NHS England and NICE. Ten procedures were added to the List across a range of medical specialties, including breast surgery, gastrointestinal surgery, cardiovascular, urology, and ophthalmology. It is expected that where treatment criteria outlined in the List for the intervention are met, it would be routinely funded.

The “New Methods” framework invited interested parties to submit information regarding microcurrent treatment for anxiety, depression, and sleep problems before August 8, 2023. Ordering Forum will then decide whether the method will undergo evaluation at the national level.

On April 28, 2023, the NHS Cancer Programme awarded £12.1 million to six innovations that improve the early detection and diagnosis of cancer. Awarded medical devices, in-vitro diagnostics, and digital health solutions are used to diagnose bowel, skin, liver, breast, ovarian, and esophageal cancer. They have proven their efficacy and clinical effectiveness and will be funded over the next 18 months to support rollout and real-world testing.

In April 2023, Swedish Medical Technologies Product (MTP) Council recommended that Magtrace and Sentimag be used for locating sentinel lymph nodes in breast cancer. The products were evaluated within the Orderly introduction framework, in which all Swedish regions collaborate to manage the national introduction of innovative medical technologies.

In March 2023, the Danish Health Technology Council (Behandlingsrådet) completed a major analysis (større analyser) on patient-centered diabetes technology. The Council recommended that sensor-based glucose monitoring devices with alarms be offered to all adult patients with type 1 diabetes.

A new preeclampsia screening algorithm has been evaluated within the "New Method" framework since 2021. The algorithm helps to predict the risk of preeclampsia in the first trimester based on several parameters, including ultrasound examination and measurement of the Placenta Growth Factor (PIGF). In March 2023, the Decision Forum for "New Method" was held and commissioned to perform the implementation study of a new screening algorithm at St. Olav's Hospital.

In January and February 2023, Ordering Forum for the “New Methods” framework invited interested parties regarding several technologies proposed for evaluation within the framework. The technologies concern arteriovenous fistula for hemodialysis, deep brain stimulation, epidural spinal cord stimulation, and digital chest drain. Ordering Forum will decide whether the technology undergoes evaluation at the national level.

In February 2023, Swedish Medical Technologies Product (MTP) Council announced ongoing horizon scanning within the Orderly introduction framework for medical technologies to be used in benign prostatic hyperplasia. The Dental and Pharmaceutical Benefits Agency (TLV) initiated a theme survey, accepting suggestions until March 31, 2023.

On January 24, 2023, the Swedish National Board of Health and Welfare recommended introducing a national screening program for spinal muscular atrophy (SMA) in newborns. It will identify children with a homozygous deletion in the SMN1 gene and 1–3 copies of the SMN2 gene. SMA testing must be included in the existing newborn screening (so-called PKU test). The launch of the new screening program is expected in the summer of 2023.